ААР — Американская академия педиатрии (American Academy of Pediatrics)
ABC — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение» (Airways-Breathing-Circulation)
АВСА3 — белковый член АТФ-связывающей кассеты АЗ
АВСВ11 — ген АТФ-связывающей кассеты, 11-й член подсемейства В (ATP-binding cassette, subfamily В member 11)
АВСВ4 — ген АТФ-связывающей кассеты, 4-й член подсемейства В (ATP-binding cassette 4 gene)
АВСС2 — ген, кодирующий 2-й член подсемейства С ABCDE — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение-неврологический статус-внешний вид» (Airways-Breathing-Circulation-Disability-Exposure)
ABCG5/G8 — гетеродимер переносчика АТФ-связывающей кассеты ABCG5 и ABCG8 (Th eheterodimer of ATP-binding cassette transporter ABCG5 and ABCG8)
AC — до еды (при назначениях) — ante cibum
АСЕР — Американская коллегия врачей неотложной помощи (American College of Emergency Physicians)
ACOG — Американская коллегия акушеров и гинекологов (American College of Obstetricians and Gynecologists)
AHA — Американская кардиологическая ассоциация (American Heart Association)
AIS — аденокарцинома in situ (adenocarcinoma in situ)
ALTE — очевидное опасное для жизни событие (apparent life-threatening event)
APLS — курсы расширенных реанимационных мероприятий в педиатрии, спонсируемые Американской академией педиатрии и Американской коллегией врачей неотложной помощи (Advanced Pediatric Life Support)
AUC — площадь под фармакокинетической кривой (area under the curve)
AVPU — шкала для оценки уровня сознания («в ясном сознании»; «реакция на вербальные раздражители»; «реакция на боль»; «без сознания») (alert, verbal, pain, unresponsive)
ABCC2 - АТФ-связывающих кассет (ATP-binding cassette sub-family C member 2)
mTOR — мишень рапамицина в клетках млекопитающих (mammalian target ofrapamycin)
NB! — важно, обратить внимание (Nota bene)
NCI — Национальный институт рака (National Cancer Institute)
NICE — Национальный институт здоровья и клинического совершенствования (качества медицинской помощи) Великобритании (National Institute for Health and Clinical Excellence)
NK — естественные клетки-киллеры (natural killer)
NMDA — N-метил-D-аспартат (N-methyl-D-aspartate)
NMDA — N-метил-D-аспартатные рецепторы
NNT — число больных, которых необходимо пролечить, чтобы достичь какого-то указанного эффекта (Number Need to Treatment)
OR — отношение шансов (odds ratio)
paCO2 — парциальное давление углекислого газа в артериальной крови
PALS — курсы расширенных реанимационных мероприятий в педиатрии (Pediatric Advanced Life Support)
PANDAS — аутоиммунное нейропсихиатрическое расстройство в детском возрасте, ассоциированное со стрептококковой инфекцией (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
PANS — острый нейропсихиатрический синдром в детском возрасте (Pediatric acute-onset neuropsychiatric syndrome)
paO2 — парциальное давление кислорода в артериальной крови
PAS — фуксинсернистая кислота, реактив Шиффа (periodic acid-Shiff)
PC — после еды (при назначениях) — post cibum рСO2 — парциальное давление углекислого газа PCSK-9 — пропротеиновая конвертаза субтилизин-кексинового типа 9 (proprotein convertase subtilisin/kexin type 9)
PD — плотность мощности (power density)
PD-1 — программируемая клеточная смерть 1 (англ. programmed cell death 1)
PFAPA — периодическая лихорадка с афтозным стоматитом, фарингитом и лимфаденитом (Periodic Fevers with Aphthous stomatitis, Pharyngitis and Adenitis)
PIM — показатель летального исхода у детей (Pediatric Index of Mortality)
piO2 — парциальное давление кислорода
во вдыхаемом воздухе
рО2 — парциальное давление кислорода
POLG — субъединица ДНК-полимеразы у
POP — пролапс тазовых органов (pelvic organ prolapse) POP-Q — количественная оценка пролапса тазовых органов (Pelvic Organ Prolapse Quantification)
PRISA II — оценка риска госпитализации у детей II (Pediatric Risk of Admission)
PRISM — риск летального исхода у детей (Pediatric Risk of Mortality)
PRN — при (по) необходимости (Pro re nata — при возникновении обстоятельств)
PRSS — ген сериновой протеазы
PS. — примечание (Post scriptum)
PUVA-терапия — псорален-ультрафиолет А-терапия (psoralen and ultraviolet А)
Q#H — каждые # часов (при назначениях) — quaque... hora
QAM — каждое утро (при назначениях) — quaque ante meridiem
QPM — каждый вечер (при назначениях) — quaque post meridiem
RAG — ген, активирующий рекомбиназу
REMS — Программа по оценке и снижению риска (Risk Evaluation and Mitigation Strategy)
RePEAT — пересмотренный инструмент для оценки педиатрической неотложной медицинской помощи (Revised Pediatric Emergency Assessment Tool)
RF — ревматоидный фактор
Rh — резус(-фактор)
Rh«+» — резус-положительный
Rh«-» — резус-отрицательный
ROCA — Алгоритм риска развития рака яичников (Risk of Ovarian Cancer Algorithm)
ROHHAD — быстро развивающееся ожирение с дисфункцией гипоталамуса, гиповентиляцией и спонтанной дисрегуляцией (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
ROMA — Алгоритм риска наличия злокачественной опухоли яичника (Risk of Ovarian Malignancy Algorithm)
RR — относительный риск (relative risk или risk ratio)
RW — реакция Вассермана (reaction of Wassermann)
SaO2 — сатурация артериальной крови кислородом
SatO2 — насыщение крови кислородом
SCJ — зона перехода плоского эпителия в цилиндрический (Scuamocolumnar Junction)
ScvO2 — насыщение кислородом центральной венозной крови (central venous oxygen saturation)
SD — стандартное отклонение (standart deviation) SEER — эпидемиология эпиднадзора и данных о конечных результатах (Surveillance Epidemiology and End Result)
SFTPA — ген сурфактантного белка A
SFTPB — ген сурфактантного белка В
SFTPC — ген сурфактантного белка С
SILS — хирургия единого лапароскопического доступа (single-incision laparoscopic surgery)
В ходе подготовки статей по недержанию мочи в гинекологии для пользователей сайта МедУнивер использованы труды следующих авторов:
Abdel-Fattah M, Mostafa A, Familusi A et al. Prospective randomised controlled trial of transobturator tapes in management of urodynamic stress incontinence in women: 3-year outcomes from the evaluation of transobturator tapes study. Eur Urol 62(5):843, 2012
Abrams P, Artibani W, Cardozo L et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 28(4):287, 2009
Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 187:116, 2002
Al-Mukhtar Othman J, ?kervall S, Milsom I et al. Urinary incontinence in nulliparous women aged 25–64 years: a national survey. Am J Obstet Gynecol 216(2):149, 2017
Amundsen CL, Richter HE, Menefee SA et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA 316:1366, 2016
Anger JT, Weinberg A, Suttorp MJ et al. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 183:2258, 2010
Bai SW, Kang JY, Rha KH et al. Relationship of urodynamic parameters and obesity in women with stress urinary incontinence. J Reprod Med 47:559, 2002
Barber MD, Gustilo-Ashby AM, Chen CC et al. Perioperative complications and adverse events of the MONARC transobturator tape, compared with the tension-free vaginal tape. Am J Obstet Gynecol 195:1820, 2006
Barber MD, Kuchibhatla MN, Pieper CF et al. Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders. Am J Obstet Gynecol 185(6):1388, 2001
Barber MD, Weidner AC, Sokol AI et al. Single-incision mini-sling compared with tension-free vaginal tape for the treatment of stress urinary incontinence: a randomized controlled trial. Obstet Gynecol 119:328, 2012
Bellin P, Smith J, Poll W et al. Results of a multicenter trial of the CapSure (Re/Stor) Continence shield on women with stress urinary incontinence. Urology 51:697, 1998
Blaivas JG: The bladder is an unreliable witness. Neurourol Urodyn 15:443, 1996
Bologna RA, Gomelsky A, Lukban JC et al. The efficacy of calcium glycerophosphate in the prevention of food-related flares in interstitial cystitis. Urology 57(6, Suppl 1):119, 2001
Brazzelli M, Murray A, Frasier C: Efficacy and safety of sacral nerve stimulation for urinary urge incontinence. A systematic review. J Urol 175:835, 2006
Brown JS, Bradley CS, Subak KK et al. The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann Int Med 144(10):715, 2006
Brown JS, Seeley DG, Fong J et al. Urinary incontinence in older women: who is at risk? Study of Osteoporotic Fractures Research Group. Obstet Gynecol 87(5 Pt 1):715, 1996
Brubaker L, Norton PA, Albo ME et al. Adverse events over two years after retropubic or transobturator midurethral sling surgery: findings from the Trial of Midurethral Slings (TOMUS) study. Am J Obstet Gynecol 205:498.e1, 2011
Brubaker L, Nygaard I, Richter HE et al. Two-year outcomes after sacrocolpopexy with and without Burch to prevent stress urinary incontinence. Obstet Gynecol 112:49, 2008a
Brubaker L, Richter HE, Visco AG et al. Refractory idiopathic urge incontinence and botulinum A injection. J Urol 180:217, 2008b
Buckley BS, Lapitan MC, Epidemiology Committee of the Fourth International Consultation on Incontinence, Paris, 2008: Prevalence of urinary incontinence in men, women, and children—current evidence: findings of the Fourth International Consultation on Incontinence. Urology 76(2):265, 2010
Bump RC, McClish DK: Cigarette smoking and urinary incontinence in women. Am J Obstet Gynecol 167:1213, 1992
Bump RC, Norton PA: Epidemiology and natural history of pelvic floor dysfunction. Obstet Gynecol Clin North Am 25:723, 1998
Burgio KL, Richter HE, Clements RH et al. Changes in urinary and fecal incontinence symptoms with weight loss surgery in morbidly obese women. Obstet Gynecol 110(5):1034, 2007
Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172(5 Pt 1):1919, 2004
Carlile A, Davies I, Rigby A et al. Age changes in the human female urethra: a morphometric study. J Urol 139:532, 1988
Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR Trial. Eur Urol 48:464, 2005
Chapple CR, Van Kerrebroeck PE, J?nemann KP et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 102(9):1128, 2008
Cody JD, Jacobs ML, Richardson K et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 4:CD001405, 2012
Colombo M, Milani R, Vitobello D et al. A randomized comparison of Burch colposuspension and abdominal paravaginal defect repair for female stress urinary incontinence. Am J Obstet Gynecol 175:78, 1996
Culligan PG, Goldberg RP, Sand PK: A randomized controlled trial comparing a modified Burch procedure and a suburethral sling: long-term follow-up. Int Urogynecol J Pelvic Floor Dysfunct 14(4):229, 2003
Dallosso HM, McGrother CW, Matthews RJ et al. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int 92:69, 2003
Deitel M, Stone E, Kassam HA et al. Gynecologic-obstetric changes after loss of massive excess weight following bariatric surgery. J Am Coll Nutr 7:147, 1988
Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78:687, 2003
Diokno AC, Brock BM, Herzog AR et al. Medical correlates of urinary incontinence in the elderly. Urology 36:129, 1990
Diokno AC, Sand PK, MacDiarmid S et al. Perceptions and behaviors of women with bladder control problems. Fam Pract 23(5):568, 2006
Dmochowski RR, Sand PK, Zinner NR et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62:237, 2003
Dumoulin C, Cacciari LP, Hay-Smith EJ: Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 10:CD005654, 2018
Dumoulin C, Hunter KF, Moore K et al. Conservative management for female urinary incontinence and pelvic organ prolapse review 2013: summary of the 5th International Consultation on Incontinence. Neurourol Urodyn 35(1):15, 2016
Fantl JA, Bump RC, Robinson D et al. Efficacy of estrogen supplementation in the treatment of urinary incontinence. The Continence Program for Women Research Group. Obstet Gynecol 88(5):745, 1996
Fantl JA, Cardozo L, McClish DK: Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 83:12, 1994
Flynn M, Amundsen CL, Perevich M et al. Short term outcomes of a randomized, double blind placebo controlled trial of botulinum A toxin for the management of idiopathic detrusor overactivity incontinence. J Urol 181(6):2608, 2009
Food and Drug Administration: Considerations about surgical mesh for SUI. 2019. Available at: https://www.fda.gov/medical-devices/urogynecologic-surgical-mesh-implants/considerations-about-surgical-mesh-sui Accessed April 21, 2019
Grady D, Brown JS, Vittinghoff E et al. Postmenopausal hormones and incontinence: the heart and estrogen/progestin replacement study. Obstet Gynecol 97:116, 2001
Gray T, Campbell P, Jha S et al. Evaluation of coital incontinence by electronic questionnaire: prevalence, associations and outcomes in women attending a urogynaecology clinic. Int Urogynecol J 29(7):969, 2018
Grodstein F, Lifford K, Resnick NM et al. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 103:254, 2004
Haab F, Corcos J, Siami P et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 98:1025, 2006
Hannestad YS, Lie RT, Rortveit G et al. Familial risk of urinary incontinence in women: population based cross sectional study. BMJ 329(7471):889, 2004
Hannestad YS, Rortveit G, Daltveit AK et al. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG 110:247, 2003
Hannestad YS, Rortveit G, Hunskaar S: Help-seeking and associated factors in female urinary incontinence. The Norwegian EPINCONT Study. Epidemiology of Incontinence in the County of Nord-Tr?ndelag. Scand J Prim Health Care 20:102, 2002
Hartmann KE, McPheeters ML, Biller DH et al. Treatment of overactive bladder in women. Evidence report/technology assessment No. 187, Rockville, Agency for Healthcare Research and Quality, 2009
Hendriks EJ, Kessels AG, de Vet HC et al. Prognostic indicators of poor short-term outcome of physiotherapy intervention in women with stress urinary incontinence. Neurourol Urodyn 29:336, 2010
Hendrix SL, Cochrane BB, Nygaard IE et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 293:935, 2005
Herschorn S, Barkin J, Castro-Diaz D et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the ?? adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 82(2):313, 2013
Holmgren C, Nilsson S, Lanner L et al. Long-term results with tension-free vaginal tape on mixed and stress urinary incontinence. Obstet Gynecol 106(1):38, 2005
Hunskaar S, Arnold EP, Burgio K et al. Epidemiology and natural history of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 11:301, 2000
Indrekvam S, Sandvik H, Hunskaar S: A Norwegian national cohort of 3198 women treated with home-managed electrical stimulation for urinary incontinence—effectiveness and treatment results. Scand J Urol Nephrol 35:32, 2001
Iosif CS, Batra S, Ek A et al. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol 141:817, 1981
Jackson SL, Scholes D, Boyko EJ et al. Predictors of urinary incontinence in a prospective cohort of postmenopausal women. Obstet Gynecol 108: 855, 2006
Janknegt RA, Hassouna MM, Siegel SW et al. Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol 39:101, 2001
Jelovsek JE, Chagin K, Brubaker L et al. A model for predicting the risk of de novo stress urinary incontinence in women undergoing pelvic organ prolapse surgery. Obstet Gynecol 123:279, 2014
Kerrebroeck PE, Voskuilen A, Heesakkers J et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 178:2029, 2007
Khan S, Panicker J, Roosen A et al. Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks. Eur Urol 57(5):891, 2010
Kirkland JL, Lye M, Levy DW et al. Patterns of urine flow and excretion in healthy elderly people. BMJ 287: 1665, 1983
Langa KM, Fultz NH, Saint S et al. Informal caregiving time and costs for urinary incontinence in older individuals in the United States. J Am Geriatr Soc 50:733, 2002
Lapitan MC, Cody DJ, Grant AM: Open retropubic colposuspension for urinary incontinence in women. Cochrane Database Syst Rev 4:CD002912, 2009
Laurikainen E, Valpas A, Aukee P et al. Five-year results of a randomized trial comparing retropubic and transobturator midurethral slings for stress incontinence. Eur Urol 65(6):1109, 2014
Lawrence JM, Lukacz ES, Liu IL et al. Pelvic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente Continence Associated Risk Epidemiology Study. Diabetes Care 30:2536, 2007
Lukacz ES, Whitcomb EL, Lawrence JM et al. Urinary frequency in community-dwelling women: what is normal? Am J Obstet Gynecol 200:552, 2009
MacDiarmid SA, Peters KM, Shobeiri SA et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol 183:234, 2010
Mallipeddi PK, Steele AC, Kohli N et al. Anatomic and functional outcome of vaginal paravaginal repair in the correction of anterior vaginal wall prolapse. Int Urogynecol J Pelvic Floor Dysfunct 12:83, 2001
Markland AD, Richter HE, Fwu CW et al. Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008. J Urol 186(2): 589, 2011
McGuire EJ: Urodynamic findings in patients after failure of stress incontinence operations. Prog Clin Biol Res 78:351, 1981
McKinley M, O’Loughlin VD: Urinary system. In Human Anatomy. New York, McGraw-Hill, 2006, p 843
Miller JJ, Botros SM, Akl MN et al. Is transobturator tape as effective as tension-free vaginal tape in patients with borderline maximum urethral closure pressure? Am J Obstet Gynecol 195:1799, 2006
Miller JJ, Sand PK: Diagnosis and treatment of overactive bladder. Minerva Ginecol 57:501, 2005
Minassian VA, Yan X, Lichtenfeld MJ et al. The iceberg of health care utilization in women with urinary incontinence. Int Urogynecol J 23:1087, 2012.
Monga AK, Stanton SL: Urodynamics: prediction, outcome and analysis of mechanism for cure of stress incontinence by periurethral collagen. BJOG 104:158, 1997
Moore EE, Jackson SL, Boyko EJ et al. Urinary incontinence and urinary tract infection: temporal relationships in postmenopausal women. Obstet Gynecol 111:317, 2008
Moser F, Bjelic-Radisic V, Tamussino K: Needle suspension of the bladder neck for stress urinary incontinence: objective results at 11 to 16 years. Int Urogynecol J 17:611, 2006
Nabi G, Cody JD, Ellis G et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4:CD0003781, 2006
Nager CW, Brubaker L, Litman HJ et al. A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med 366(21):1987, 2012
Neuman M: Perioperative complications and early follow-up with 100 TVT-SECUR procedures. J Minim Invasive Gynecol 15(4):480, 2008
Nilsson CG, Palva K, Aarnio R et al. Seventeen years’ follow-up of the tension-free vaginal tape procedure for female stress urinary incontinence. Int Urogynecol J 24(8):1265, 2013
Noblett K, Lane FL, Driskill CS: Does pelvic organ prolapse quantification exam predict urethral mobility in stages 0 and I prolapse? Int Urogynecol J Pelvic Floor Dysfunct 15:268, 2005
Nygaard I: Is cesarean delivery protective? Semin Perinatol 30:267, 2006
Nygaard I, Barber MD, Burgio KL et al. Prevalence of symptomatic pelvic floor disorders in U.S. women. JAMA 300(11): 1311, 2008
Nygaard I, Brubaker L, Zyczynski HM et al. Long-term outcomes following abdominal sacrocolpopexy for pelvic organ prolapse. JAMA 309:2016, 2013
O’Connor RC, Nanigian DK, Lyon MB et al. Early outcomes of mid-urethral slings for female stress urinary incontinence stratified by Valsalva leak point pressure. Neurourol Urodyn 25:685, 2006
Ouslander JG: Management of overactive bladder. N Engl J Med 350(8):786, 2004
Pearce MM, Hilt EE, Rosenfeld AB et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. MBio 5(4):e01283, 2014
Peters KM, Carrico DJ, Perez-Marrero RA et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 183:1438, 2010
Peters KM, MacDiarmid SA, Wooldridge LS et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 182:1055, 2009
Petros PE, Ulmsten UI: An integral theory of female urinary incontinence. Experimental and clinical considerations. Scand J Urol Nephrol 153(Suppl):1, 1993
Rahn DD, Carberry C, Sanses TV et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 124(6):1147, 2014
Rahn DD, Ward RM, Sanses TV et al. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J 26(1):3, 2015
Raz R, Stamm WE: A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329:753, 1993
Resnick NM: Voiding dysfunction in the elderly. In Yalla SV, McGuire EJ, Elbadawi A, et al (eds): Neurourology and Urodynamics: Principles and Practice. New York, Macmillan, 1984, p 303
Resnick NM, Elbadawi A, Yalla SV: Age and the lower urinary tract: what is normal? Neurourol Urodyn 14:577, 1995
Richter HE, Albo ME, Zyczynski HM et al. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med 362(22):2066, 2010a
Richter HE, Burgio KL, Brubaker L et al. Continence pessary compared with behavioral therapy or combined therapy for stress incontinence. A randomized controlled trial. Obstet Gynecol 115(3):609, 2010b
Rortveit G, Daltveit AK, Hannestad YS et al. Urinary incontinence after vaginal delivery or cesarean section. N Engl J Med 348(10):900, 2003a
Rortveit G, Daltveit AK, Hannestad YS et al. Vaginal delivery parameters and urinary incontinence: the Norwegian EPINCONT study. Am J Obstet Gynecol 189(5):1268, 2003b
Sahai A, Dowson C, Khan MS et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 75(3):552, 2010
Sahai A, Khan MS, Dasgupta P: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177(6):2231, 2007
Sand P, Zinner N, Newman D et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 99(4):836, 2007
Sand PK, Bown LW, Panganiban R et al. The low pressure urethra as a factor in failed retropubic urethropexy. Obstet Gynecol 62:399, 1987
Schmidt RA, Jonas UD, Oleson KA et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol 162:352, 1999
Serati M, Salvatore S, Uccella S et al. Female urinary incontinence during intercourse: a review on an understudied problem for women’s sexuality. J Sex Med 6:40, 2009
Siegel SW, Catanzaro F, Dijkema HE et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 56(6 Suppl 1):87, 2000
Sirls LT, Foote JE, Kaufman JM et al. Long-term results of the FemSoft1 Urethral Insert for the management of female stress urinary incontinence. Int Urogynecol J 13:88, 2002
Song PH, Kim YD, Kim HT et al. The 7-year outcome of the tension-free vaginal tape procedure for treating female stress urinary incontinence. BJU Int 104(8):1113, 2009
Snooks SJ, Swash M, Henry MM et al. Risk factors in childbirth causing damage to the pelvic floor innervation. Int J Colorectal Dis 1:20, 1986
Subak LL, Wing R, West DS et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 360(5):481, 2009
Swift SE, Bent AE: Basic evaluation of the incontinent female patient. In Bent AE, Cundiff GW, Swift SE (eds): Ostergard’s Urogynecology and Pelvic Floor Dysfunction, 6th ed. Philadelphia, Lippincott Williams & Wilkins, 2008, p 67
Townsend MK, Curhan GC, Resnick et al. The incidence of urinary incontinence across Asian, black, and white women in the United States. Am J Obstet Gynecol 202:378.e1, 2010
Versi E1, Griffiths DJ, Harvey MA: A new external urethral occlusive device for female urinary incontinence. Obstet Gynecol 92:286, 1998
Vervest HA, van Venrooij GE, Barents JW et al. Non-radical hysterectomy and the function of the lower urinary tract. II: Urodynamic quantification of changes in evacuation function. Acta Obstet Gynecol Scand 68:231, 1989
Visco AG, Brubaker L, Richter HE et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med 367:1803, 2012
Wai CY, Curto TM, Zyczynski HM et al. Patient satisfaction after midurethral sling surgery for stress urinary incontinence. Obstet Gynecol 121(5):1009, 2013
Wake CR: The immediate effect of abdominal hysterectomy on intravesical pressure and detrusor activity. BJOG 87:901, 1980
Wang AC, Wang YY, Chen MC: Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology 63:61, 2004
Weber AM: Leak point pressure measurement and stress urinary incontinence. Curr Womens Health Rep 1:45, 2001
Wei JT, Nygaard I, Richter HE et al. A midurethral sling to reduce incontinence after vaginal prolapse repair. N Engl J Med 366(25):2358, 2012
Wester C, Fitzgerald MP, Brubaker L et al. Validation of the clinical bulbocavernosus reflex. Neurourol Urodyn 22:589, 2003
Wing RR, Creasman JM, West DS et al. Improving urinary incontinence in overweight and obese women through modest weight loss. Obstet Gynecol 116:284, 2010
Wu JM, Hundley AF, Fulton RG et al. Forecasting the prevalence of pelvic floor disorders in U.S. women 2010 to 2050. Obstet Gynecol 114(6):1278, 2009
Wu JM, Vaughan CP, Goode PS et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol 123:141, 2014
Zimmern P, Litman HJ, Nager CW et al. Effect of aging on storage and voiding function in women with stress predominant urinary incontinence. J Urol 192:464, 2014
Zinner N, Gittelman M, Harris R et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171(6 Pt 1):2311, 2004
Труды отечественных авторов при подготовке статей по гинекологии для пользователей сайта - не использовались, так как их вы всегда можете найти в библиотеках.
